Samsung Securities: After Samsung Biologics acquires a US factory, its new contracts are expected to increase.

Samsung Securities analyst Keunhee Seo wrote in a report that Samsung Biologics' decision to acquire a US drug manufacturing plant may significantly increase its contract pipeline. The South Korean contract development and manufacturing organization has decided to acquire 100% of Genome Sciences, located in Rockville, Maryland, which is currently owned by GSK, for $280 million. Seo stated that the 60,000-liter production facility in the US could lead to Samsung Biologics securing a series of new CDMO agreements with large global pharmaceutical clients that prefer manufacturing in the United States. He added that the pending Biosecurity Act, aimed at reducing US pharmaceutical companies' dependence on the Chinese supply chain, could also help Samsung Biologics secure additional contracts.